Compare AbCellera Biologics Inc (ABCL) vs Nike Inc (NKE) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Nike (NKE) trades at $43.34, down 1.7% on the day, with a bearish technical signal and mixed sentiment. Recent earnings have consistently beaten estimates, but revenue declined to $46.31B in 2025 with net income falling to $3.22B. The stock shows strong profitability margins and a P/E of 20.64, while analysts maintain a consensus Buy rating with a $50.67 price target. Key support lies at $42, with resistance at $44.

Nike faces near-term headwinds from sluggish consumer demand and margin pressure, but its brand strength and digital direct-to-consumer strategy provide long-term upside potential. Risks include inventory challenges and economic sensitivity, yet institutional confidence remains with 48.6% analyst Buy ratings. The upcoming Q4 2026 earnings on June 30, 2026, will be critical for confirming turnaround progress.